<p><strong>Adults</strong>: Orlistat is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI)&gt;30 kg/m2&nbsp;and overweight patients (BMI &gt;28 kg/m2&nbsp;) with associated risk factors such as type II diabetes, hyperlipidemia and hypertension. Treatment with Orlistat should be discontinued after 12 weeks in patients who have not lost at least 5% of their body weight as measured at the start of drug therapy.<br />
<br />
<strong>Adolescents (12 years &amp; older)</strong>: Obese adolescents should be treated with Orlistat only if an adequate reduction of body weight cannot be achieved by means of diet &amp; increased physical activity. Treatment with orlistat should be considered in particular if complications of obesity are present.</p>